Long-Term Effectiveness and Safety of SGLT-2 Inhibitors in an Italian Cohort of Patients with Type 2 Diabetes Mellitus

Table 2

Reasons and time for treatment discontinuation in patients who were treated with SGLT-2 inhibitors.

	Patients, (%)	Months, median (IQR)
Chronic or recurring genital yeast infections	66 (67.4)	7.5 (3-12)
Persistent or recurring urinary tract infections	11 (11.2)	6 (3-12)
Other adverse events^a	21 (21.4)	3 (1-9)
Overall	98 (100)	6 (2-12)

^aPolyuria, nausea, hypotension, dizziness, acute coronary event, worsening of glycemic control, and rapid deterioration of renal function.